by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Slides:

Advertisements

Similar presentations

Palumbo A et al. Proc ASH 2012;Abstract 446.

Advertisements

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Reeder CB et al. ASCO 2009; Abstract (Poster)

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic.

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study by Guillaume Cartron, Sophie de Guibert,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

Volume 70, Issue 5, Pages (November 2016)

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL by Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés,

by Michael F. Leahy, and J. Harvey Turner

How I treat refractory CLL

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells by Barbara Withers, Emily Blyth,

A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease Paul A. Carpenter,

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Overall survival by SCT versus observation in first complete remission

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease by Jennifer S. Whangbo, Haesook.

Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Plasma biomarker concentrations between study groups.

Supplementary Figure S1

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy by Wyndham H. Wilson, Michael L. Grossbard,

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

by Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.

by Lapo Alinari, and Kristie A. Blum

Genomic determinants of response to cytotoxic chemotherapy.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma by Alex F. Herrera, Alison.

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Survival, subsequent therapies, and response.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Ronan T. Swords, Steven Coutre, Michael.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Cold agglutinin disease

Presentation transcript:

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J. Siegel, Amanda F. Cashen, Kristie A. Blum, Timothy S. Fenske, David D. Hurd, Andre Goy, Stephanie E. Schneider, Catherine R. Keppel, Nina D. Wagner-Johnston, Kenneth R. Carson, and Nancy L. Bartlett Blood Volume 118(19):5119-5125 November 10, 2011 ©2011 by American Society of Hematology

Summary of lenalidomide administration. Summary of lenalidomide administration. Graphical summary of lenalidomide administration to 38 cHL patients, with individual patients on the y-axis and the number of cycles and dose of lenalidomide administered on the x-axis. If an intra-cycle dose reduction was performed, the lowest dose used for a given cycle is indicated. Lenalidomide was administered on days 1-21 of a 28-day cycle, initiated at 25 mg/d. *Ongoing lenalidomide therapy. Todd A. Fehniger et al. Blood 2011;118:5119-5125 ©2011 by American Society of Hematology

Waterfall plot of maximal decrease in sum of the products of the greatest diameter from baseline (before therapy) for 35 cHL patients treated with ≥ 2 cycles of lenalidomide. Waterfall plot of maximal decrease in sum of the products of the greatest diameter from baseline (before therapy) for 35 cHL patients treated with ≥ 2 cycles of lenalidomide. Two patients who went off-study during cycle 1 or 2 of lenalidomide because of AEs are not included, and off-study data from 1 patient with rapidly progressive disease during cycle 1 were not available. Patients with CR, PR, or SD > 6 months are annotated. Todd A. Fehniger et al. Blood 2011;118:5119-5125 ©2011 by American Society of Hematology

Kaplan-Meier PFS and OS estimates. Kaplan-Meier PFS and OS estimates. Survival analysis included 35 patients with evaluable disease completing at least 2 cycles of lenalidomide. Median PFS was 4 months (95% CI: 2-6) and the median OS was 20 months (95% CI: 15-NE). Todd A. Fehniger et al. Blood 2011;118:5119-5125 ©2011 by American Society of Hematology

CCL17/TARC and CCL22/MDC changes. CCL17/TARC and CCL22/MDC changes. Shown are CCL17/TARC and CCL22/MDC changes from pretherapy cycle 1 day 1 (C1D1) and cycle 1 day 15 (C1D15) for responders (CR/PR/SD ≥ 6 months) and nonresponders (SD < 6 months, PD). Box-whisker plots depict pretherapy and C1D15 plasma CCL17 or CCL22 concentrations. P values were determined using the Wilcoxon signed rank test. There was no significant difference between C1D1 and C1D15 in nonresponders. Todd A. Fehniger et al. Blood 2011;118:5119-5125 ©2011 by American Society of Hematology